Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (15413)	6/22/2001 7:30:49 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Gw, Biogen is a great position, Amevive is a great drug, I post just yesterday that if more than 10% of subjects are good responders the drug is plain excellent. These short term fluctuations are not the full story, just yesterday xoma seems doom. I was truly amazed at the manipulation and I expressed so to Bluegreen dismay! Today the story on Biogen was not Amevive at all but the perception of Serono drug as a threat to Avonex. There is not such a threat (except the European contra US), but nice to scare and take away the shares. Biogen shares are going to be $85 end of year, above $100 in one year, before selling a drop of IV or IM Amevive! The same way xoma is like 100% from the bottom, and with much less risk in a Biogen position! Biogen is at the bottom of its 52 week trading range, has close to $1 billion in sales. xoma now has chance to bring 2 to 3 million shares in the upper teen$ to the market, if they do have money till next year maybe in the $20s. xoma/dna can file a modular piece of the BLA and bring the rest after April, good for more news. By the way, have you ever recognized that Amevive is a great drug? Have you ever look at it from the Biogen perspective? The same "fusion" technology that is used in Amevive you love in xoma PRECLINICAL! All well that ends shortly!